Live price temporarily unavailable.
PepGen (PEPG) is a Health Care company. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Operating income | −$27.1M | −$68.3M | −$84.8M | −$97.7M | −$93.6M |
| Net income | −$27.3M | −$69.1M | −$78.6M | −$90.0M | −$89.7M |
| EPS (diluted) | −$30.27 | −$4.42 | −$3.30 | −$2.85 | −$2.12 |
| Balance sheet | |||||
| Cash and equivalents | $132.9M | $181.8M | $80.8M | $49.4M | $60.5M |
| Total assets | $143.6M | $217.4M | $143.1M | $150.9M | $173.9M |
| Total liabilities | $10.5M | $37.8M | $34.6M | $32.3M | $26.5M |
| Shareholders' equity | −$32.1M | $179.6M | $108.4M | $118.6M | $147.4M |
| Cash flow | |||||
| Operating cash flow | −$22.6M | −$59.3M | −$69.0M | −$82.4M | −$81.6M |
| Capital expenditure | $500.0K | $3.75M | $2.60M | $497.0K | $264.0K |
| Free cash flow | −$23.1M | −$63.0M | −$71.6M | −$82.9M | −$81.9M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$23.2M | −$24.3M | −$31.3M | −$23.9M | −$18.7M | −$19.7M | −$18.9M | −$18.9M |
| Net income | −$21.4M | −$22.2M | −$30.2M | −$23.1M | −$18.0M | −$18.3M | −$17.8M | −$17.8M |
| EPS (diluted) | −$0.66 | −$0.69 | −$0.92 | −$0.70 | −$0.52 | $0.02 | −$0.26 | −$0.26 |
| Balance sheet | ||||||||
| Cash and equivalents | $42.3M | $49.4M | $43.6M | $35.1M | $142.8M | $60.5M | $42.1M | $22.8M |
| Total assets | $170.2M | $150.9M | $127.4M | $102.2M | $190.1M | $173.9M | $156.3M | $141.4M |
| Total liabilities | $32.8M | $32.3M | $35.6M | $31.1M | $26.9M | $26.5M | $22.3M | $21.9M |
| Shareholders' equity | $137.5M | $118.6M | $91.8M | $71.2M | $163.1M | $147.4M | $134.0M | $119.5M |
| Cash flow | ||||||||
| Operating cash flow | −$24.0M | −$19.5M | −$22.9M | −$23.6M | −$19.3M | −$15.8M | −$18.4M | −$15.8M |
| Capital expenditure | $185.0K | $228.0K | $125.0K | $43.0K | $97.0K | −$1.00K | $0 | $30.0K |
| Free cash flow | −$24.2M | −$19.7M | −$23.1M | −$23.6M | −$19.4M | −$15.8M | −$18.4M | −$15.8M |
From PepGen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning PepGen in our feed yet.